Building on a decade of successful business in North America, powder characterisation specialist Freeman Technology has formally established its US subsidiary, Freeman Technology Inc.
This new organisation will take responsibility for sales, service and applications support for the FT4 Powder Rheometer in the US, and will work with prospective customers across all industrial markets.
To support this move, Mike Delancy has joined Freeman Technology Inc as national sales specialist adding a wealth of commercial and rheological applications experience to the established Freeman Technology team.
Sales of the Freeman Technology FT4 Powder Rheometer have grown year-on-year since the instrument’s introduction more than 10 years ago, with North America an increasingly active market in the pharmaceutical and other powder processing sectors.
Freeman Technology formally establishes US subsidiary
Appoints Mike Delancy as national sales specialist
You may also like
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)
Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)
As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
